How to Treat PTSD: Therapy, Medication, and New Options

Most people wait years before getting effective PTSD treatment.

Not because effective treatments do not exist. They do, and the evidence behind them is some of the strongest in all of psychiatry. The gap is access: to clinicians who specialize in trauma, to evidence-based therapies that are time-intensive to deliver, and to the basic clinical continuity needed to work through trauma-focused protocols without abandoning them mid-process.

The result is that PTSD becomes an undertreated, often misdiagnosed condition that shapes how people sleep, relate to others, manage daily demands, and respond to medication for everything else.

The treatment picture has also shifted. Updated guidelines from both the VA/DoD (2023) and the American Psychological Association (2024-2025) now reflect a stronger evidence base than ever, clearer prioritization of psychotherapy over medication, and a broader recognition of PTSD’s complexity in real-world presentations.

Understanding what those treatments are, how they work, and when medication fits into the picture is the starting point for actually getting better.

What This Page Covers

• The three evidence-based therapies with the strongest evidence for PTSD
• How each works and what distinguishes them
• What the 2023-2025 guideline updates changed
• When medication helps and which medications are supported
• Emerging treatments on the clinical horizon
• Comorbid conditions and why they matter for treatment planning
• How SiggyMD supports PTSD-related depression and anxiety

The Three Core Psychotherapies

Both the VA/DoD (2023) and the APA (2024-2025) guidelines recommend three individual trauma-focused psychotherapies as the first-line treatments for PTSD in adults. These are the interventions with the largest and most consistent evidence base.

Cognitive Processing Therapy (CPT)

CPT is a cognitive behavioral therapy-based program that helps patients process trauma by examining and modifying trauma-related beliefs. It is typically delivered over 12 sessions and addresses what the patient thinks about the trauma itself, about themselves as a result of the trauma, and about the world going forward.

CPT does not require patients to repeatedly narrate the traumatic event in extended detail, which distinguishes it from prolonged exposure. Instead, it uses structured written exercises (including an initial trauma account) and worksheets to help patients identify “stuck points”: overgeneralized or distorted beliefs that keep them trapped in trauma responses.

Clinical trials show that 70 to 80 percent of people who complete CPT experience significant reductions in PTSD symptoms. The therapy specifically targets five content areas where trauma disrupts beliefs: safety, trust, power and control, esteem, and intimacy. Drop-out rates from CPT are lower than from prolonged exposure, making it more accessible for patients who struggle with extended trauma-focused exposure.

Prolonged Exposure (PE)

Prolonged exposure works by having patients systematically confront trauma-related memories and situations that have become avoided. This includes imaginal exposure (mentally revisiting the traumatic memory in session) and in vivo exposure (approaching avoided situations in real life that are now objectively safe).

The theory behind PE is that traumatic memories are not emotionally processed at the time of the event and remain represented in memory as an active fear structure. Repeated exposure to the memory in a safe context, without the feared consequences occurring, gradually extinguishes the fear response. The treatment typically requires 8 to 15 sessions.

PE is highly effective but has higher dropout rates than CPT, particularly among patients who find repeated trauma narration intolerable. It is often more suitable for patients with a single, well-defined traumatic event than for those with complex, repeated trauma.

EMDR

Eye movement desensitization and reprocessing (EMDR) guides patients to revisit traumatic memories while engaging in bilateral stimulation, typically following the therapist’s moving hand with their eyes. The processing occurs in structured sets of dual attention, alternating between the traumatic memory and the external stimulus.

EMDR’s mechanism of action remains partly debated in the research literature. Some studies suggest the bilateral movement contributes; others indicate the exposure component is primary. Regardless of mechanism, the treatment evidence is strong. Both the VA/DoD and APA guidelines recommend EMDR, and a 2025 review of meta-analyses confirmed its long-term efficacy.

EMDR is valued for patients who have difficulty narrating their trauma verbally, those with complex multi-event trauma histories, and those who prefer a less verbally intensive approach. It typically runs 8 to 12 sessions.

What the 2023-2025 Guideline Updates Changed

The VA/DoD CPG (2023) and the APA’s Clinical Practice Guideline for the Treatment of PTSD in Adults (2025) both reinforce the same fundamental hierarchy: individual trauma-focused psychotherapy over medications as the primary PTSD intervention, based on superior long-term outcomes and fewer adverse effects.

The 2025 APA guideline is particularly significant. It drew from 15 systematic reviews rather than the single systematic review behind the 2017 guideline, and it expanded the outcomes evaluated beyond PTSD symptom reduction to include substance use, affect dysregulation, suicidal ideation, dissociation, quality of life, and functional outcomes. CPT, PE, and trauma-focused CBT were rated as the three highest-evidence interventions.

EMDR received a second-tier “suggested” recommendation, meaning it has meaningful evidence but slightly less consistency across diverse populations than the first-tier three. SSRIs and SNRIs also received conditional recommendations, with the guideline specifying that offering medication alongside therapy is appropriate when therapy is not preferred or not accessible.

The guidelines also addressed MDMA-assisted therapy (currently under FDA review) and ketamine, finding the current evidence too preliminary to make formal recommendations but acknowledging ongoing active trials.

Medication for PTSD

Only sertraline (Zoloft) and paroxetine (Paxil) carry FDA approval specifically for the treatment of PTSD. Fluoxetine and venlafaxine are used off-label with meaningful supporting evidence and are frequently prescribed in clinical practice.

SSRIs and SNRIs are typically the first-choice medications for PTSD. They reduce hyperarousal symptoms, improve sleep (in some patients), and address the comorbid depression and anxiety that affect most people with PTSD. Prazosin is sometimes prescribed specifically for PTSD-related nightmares, with evidence supporting its use in this specific symptom domain.

Medication does not process the underlying trauma. It manages symptoms, reduces the severity of re-experiencing and hyperarousal, and improves the physiological capacity to engage in therapy. This is the right framing for understanding when and why to use it.

For people with severe PTSD who are struggling to function, or who have comorbid depression severe enough to interfere with engaging in trauma work, medication provides the stabilization needed before therapy begins. Evidence from the VA/DoD guideline review confirmed that the presence of comorbid conditions does not alter the effectiveness of CPT and PE, but the comorbidity does need to be considered in treatment sequencing.

Comorbid Conditions: The Clinical Reality of PTSD

PTSD rarely exists in isolation. The majority of people with PTSD have at least one co-occurring psychiatric condition, most commonly major depression, generalized anxiety disorder, and substance use disorders. These comorbidities affect both the presentation of PTSD and the approach to treatment.

For depression and anxiety specifically: getting these conditions under better clinical management through SSRIs and appropriate therapy significantly improves a person’s capacity to engage in trauma-focused work. The stress tolerance, emotional regulation, and therapeutic alliance needed to engage in CPT or EMDR are all affected by severe depression or anxiety, and addressing those first creates a better foundation for trauma processing.

This sequencing is not always linear. In many cases, PTSD treatment and medication for depression can proceed simultaneously, with the medication providing support for engagement in therapy from the beginning.

About SiggyMD

PTSD rarely travels alone. Depression and anxiety are among the most common co-occurring conditions, and they are often the conditions that bring someone to a clinician before they recognize the PTSD itself.

SiggyMD provides clinician-supervised medication management for anxiety and depression, with daily check-ins and prescriber access between appointments. For people working through PTSD who also need medication support for depression or anxiety, having a care relationship that monitors symptoms in real time, rather than waiting for quarterly appointments, changes what is possible in managing the day-to-day impact of trauma.

SiggyMD does not provide trauma-focused psychotherapy directly. What it provides is the medication management layer that supports the psychiatric conditions that co-occur with PTSD and that, when adequately treated, make engagement in trauma-focused therapy more possible.

“Most people who come to us managing anxiety and depression have trauma in their history that was never adequately addressed,” says Daniel Montville, MD, Psychiatrist, of the SiggyMD clinical team. “Getting the depression and anxiety treated changes daily functioning. It also changes what people are capable of in terms of actually showing up for trauma work.”

SiggyMD’s anonymous intake requires no name, email, or account to begin. A licensed prescriber reviews the full clinical picture before anything is prescribed.

For more on conditions that often accompany PTSD, read our guides on living with PTSD long-term or Complex PTSD vs. PTSD.

Start your anonymous intake at SiggyMD to connect with a licensed prescriber who can help with the depression and anxiety that frequently accompany PTSD.

What Members Are Saying

CJ

C.J., 36

PTSD with Comorbid Depression

“I kept being told I had treatment-resistant depression, but the depression was downstream of the trauma. Getting the depression managed pharmacologically made it possible to actually show up for CPT without being too depleted to do the work. Both had to happen. Neither one alone would have been enough.”

NS

N.S., 28

PTSD and Anxiety Management

“The thing that surprised me most was how much having someone check in between sessions mattered. My anxiety spiked badly in the weeks I was doing trauma processing. Having a prescriber who could see that in real time, not two months later, meant we could respond to it.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. You can begin anonymous intake without an account, name, email, or payment.

The Bottom Line

Effective PTSD treatment exists and has decades of clinical trial evidence behind it. CPT, PE, and EMDR are the three highest-evidence individual trauma-focused therapies, consistently recommended by both VA/DoD and APA guidelines. Psychotherapy outperforms medication as a standalone treatment, though medication plays a meaningful role in managing comorbid conditions and supporting engagement in therapy.

The central challenge in PTSD care is not that treatments do not work. It is that access to clinicians trained in evidence-based protocols remains limited, and that comorbid depression and anxiety often go undertreated in ways that make trauma work harder. Addressing those co-occurring conditions is part of effective PTSD treatment, not separate from it.

Sources

1. American Psychological Association. Treatments for PTSD. Updated 2024-2025.

2. VA National Center for PTSD. Overview of Psychotherapy for PTSD. Updated 2023.

3. Hamblen JL, Norman SB, Sonis JH, et al. A Guide to Guidelines for the Treatment of PTSD. Curr Psychiatry Rep. 2019.

4. Hamblen JL, Schnurr PP. A Review of PTSD and Current Treatment Strategies. J Clin Outcomes Manag. 2021.

5. Hoppen TH, et al. PTSD and Complex PTSD, Current Treatments and Debates: A Review of Reviews. Front Psychiatry. 2025.

6. APA Monitor on Psychology. CE Corner: PTSD and Trauma: New APA Guidelines Highlight Evidence-Based Treatments. July-August 2025.

7. Harvard Health Publishing. PTSD: How Is Treatment Changing? May 2024.

8. Anxiety and Depression Association of America. Post-Traumatic Stress Disorder (PTSD): Treatment Facts. Accessed June 2026.